VAPOTHERM REINFORCES LEADERSHIP ROLE WITH PATENT FOR APPARATUS AND METHOD FOR RESPIRATORY TRACT THERAPY
STEVENSVILLE, Md., Jan. 22 /PRNewswire-USNewswire/ -- Vapotherm, the global leader in High Flow Oxygen Therapy products, announced today that U.S. patent rights have been validated for an apparatus used in the delivery tube technology for respiratory tract therapy. Reinforcing Vapotherm's principal role in the industry, the U.S. Patent No. 7,314,046 B2 has been granted through 2022 and provides Vapotherm the right to prevent or exclude other companies from making, using, selling, or offering to sell or import the invention.
The triple lumen design is the vital component for Vapotherm products as it helps deliver humidified air to the respiratory tract of patients. Used throughout all Vapotherm products, including the 2000i and the recently introduced Precision Flow(TM), the apparatus allows Vapotherm to maintain the conditioned breathing gases to the patient and thus aid with respiratory tract therapy and treatment.
"Our patient delivery circuit design is unique in the field and provides Vapotherm with a competitive advantage through the delivery of optimally conditioned breathing gases all the way to the patient, whereas conventional approaches can result in significant temperature and humidity loss," said William Niland, Chairman and Chief Business Development Officer at Vapotherm.
Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and home care use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive technologies for respiratory therapy, especially for the treatment of chronic lung and acute breathing disorders. For more information, visit http://www.vtherm.com.
Amy Elias/Brian Johnson
|SOURCE Vapotherm, Inc.|
Copyright©2008 PR Newswire.
All rights reserved